In vivo studies have shown that IL-17A-deficient mice were partially protected by bleomycin-induced scleroderma [30], and bleomycin-induced scleroderma was attenuated by anti-IL-17A antibody [31]. This evidence concerns the gene IL17A and scleroderma.